Fortress Biotech, Inc. (FBIO)

Over the past six months, Fortress Biotech's stock has experienced several notable events. FBIO's share price was around $2.40 as of early May 2026, decreasing by 34.7% since the beginning of 2026 but increasing by 42.01% over the past year. The FDA approved ZYCUBO for Menkes disease in January 2026, and a priority review voucher was sold for $205 million in February 2026. Avenue Therapeutics entered an exclusive worldwide license agreement for ATX-04 for the treatment of Pompe Disease. Fortress Biotech reported Q3 2025 revenue of $17.6 million and EPS of $0.11. The company reported a full-year 2025 loss per share of US$0.067 and revenue of $63.26 million. Fortress Biotech is scheduled to report Q1 2026 results on May 13, 2026. Alliance Global analyst Scott Henry raised the firm's price target on FBIO to $4.50 and maintained a Buy rating. The company has a consensus rating of "Hold" with an average price target of $17.00. Shares of Fortress Biotech underwent a 1-for-15 reverse stock split on October 10, 2023.

The provided search results do not contain specific information regarding demand seasonality for Fortress Biotech, Inc.'s products and services. The nature of biopharmaceutical products may not typically exhibit strong seasonal demand fluctuations compared to consumer goods.

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. The company operates in the healthcare sector, specifically in pharmaceutical preparation manufacturing and biotechnology. Their business model aims to enhance shareholder value through product revenue, equity holdings, and dividend and royalty income from a portfolio of prescription products and development programs. The company's portfolio includes oncology, dermatology, and rare diseases. Fortress Biotech has marketed prescription pharmaceutical products and numerous programs in development, both directly and through its partners and subsidiaries. Major marketed dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm, Ximino and Luxamend. Late-stage product candidates include Cosibelimab, DFD-29, ZYCUBO, and IV Tramadol.

Fortress Biotech, Inc. is headquartered in Bay Harbor Islands, Florida, with an additional office in Waltham, Massachusetts, United States. The company's products, such as ZYCUBO, have received FDA approval, indicating a primary market focus in the United States.

Information specifically detailing events that have affected Fortress Biotech, Inc.'s brand reputation in the past year is limited in the provided search results. While the company was ranked in the Deloitte Technology Fast 500 in 2019, no recent accolades or significant negative reputation-impacting events from the last year were explicitly found.

Fortress Biotech has a diverse ownership structure. Approximately 8.75% to 5.62% of the company's stock is owned by institutional investors, 27.33% by insiders, and 63.92% by public companies and individual investors. Lindsay Rosenwald owns the most shares of Fortress Biotech. Major institutional owners include Vanguard Group Inc., Opaleye Management Inc., Summit Financial, LLC, Shikiar Asset Management Inc., Geode Capital Management, Llc, Gsa Capital Partners Llp, Northern Trust Corp, Susquehanna International Group, Llp, Sculptor Capital LP, BlackRock, Inc., Kestra Advisory Services LLC, 180 Wealth Advisors LLC, Panagora Asset Management Inc., Envestnet Asset Management Inc., Cambridge Investment Research Advisors Inc., and Osaic Holdings Inc.